Laniquidar

Laniquidar
	File:Laniquidar.png
Systematic (IUPAC) name
	methyl 11-(1-{2-[4-(quinolin-2-ylmethoxy)phenyl]ethyl}piperidin-4-ylidene)-6,11-dihydro-5H-imidazo[2,1-b][3]benzazepine-3-carboxylate
Identifiers
CAS Number	197509-46-9
ATC code	none
PubChem	CID 6450806
Chemical data
Formula	C37H36N4O3
Molar mass	584.70 g/mol[[Script error: No such module "String".]]

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Laniquidar (INN) is a P-glycoprotein inhibitor undergoing clinical studies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).^[1]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

This pharmacology-related article is a stub. You can help ssf by expanding it.

↑ Ross DD. Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. Best Pract Res Clin Haematol 2004;12;17(4):641-51. PMID 15494300